SCHEDULE: Deep Track Capital Discloses 9.53% Stake in Ocular Therapeutix

Deep Track Capital, LP, along with its affiliates, has reported beneficial ownership of 9.53% of Ocular Therapeutix, Inc. common stock as of March 31, 2026.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have jointly filed a Schedule 13G, indicating their beneficial ownership of Ocular Therapeutix, Inc. common stock.
• As of March 31, 2026, the reporting persons collectively beneficially own 20,850,000 shares of Ocular Therapeutix, Inc. common stock.
• This ownership represents 9.53% of the class of securities outstanding.
• The filing notes that the beneficial ownership includes 1,163,718 Pre-Funded Warrants exercisable into common shares, subject to a 9.99% maximum exercise limitation.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports an existing ownership stake and does not contain new operational or financial performance data, nor does it indicate immediate strategic shifts.

Positives

• Significant ownership stake of 9.53% in Ocular Therapeutix, Inc. by Deep Track Capital and its affiliates, indicating strong investor confidence.
• The reporting persons have shared power to dispose of 20,850,000 shares, demonstrating substantial control over a significant portion of their holdings.

Negatives

• The beneficial ownership is subject to a 9.99% maximum percentage exercise limitation for Pre-Funded Warrants, which could restrict the full exercise of these warrants.

Risks

• The 9.99% 'Maximum Percentage' limitation on exercising Pre-Funded Warrants could prevent the reporting persons from fully converting these warrants into common stock, potentially limiting their influence or economic benefit.
• Future changes in the reporting persons' investment strategy or market conditions could lead to a reduction in their stake in Ocular Therapeutix, Inc.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Ocular Therapeutix, Inc. It primarily reports on the ownership stake of Deep Track Capital and its affiliates.

Management Comments

• David Kroin, Managing Member of the General Partner of the Investment Adviser of Deep Track Capital, LP, certified that the securities were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.
• David Kroin, Director of Deep Track Biotechnology Master Fund, Ltd., provided similar certification regarding the acquisition and holding of securities.
• David Kroin certified that the information set forth in the statement is true, complete, and correct.

Industry Context

StockSavvy.ai notes that significant stake disclosures via Schedule 13G filings often signal substantial investor interest, potentially influencing market perception and strategic discussions within the biotechnology and pharmaceutical sectors, particularly for companies like Ocular Therapeutix focused on ophthalmic solutions.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by Deep Track Capital may influence investor sentiment and potentially lead to increased trading activity. Other shareholders may look to this significant holder for cues on future company direction.
• Management and Board of Directors: The increased ownership by Deep Track Capital may lead to closer scrutiny of company performance and strategy by the reporting persons, potentially influencing board decisions or strategic initiatives.

Next Steps

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin will continue to monitor their investment in Ocular Therapeutix, Inc.
• The reporting persons will file amendments to this Schedule 13G as required by SEC regulations to reflect any material changes in their beneficial ownership.

Key Dates

Keywords

Ocular Therapeutix, Schedule 13G, Deep Track Capital, Beneficial Ownership, Common Stock, Pre-Funded Warrants, SEC Filing, Investment Management